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► red cell distribution
width
Abstract Introduction Red cell distribution width (RDW) is associated with cardiovascular
diseases, including atrial fibrillation (AF) and venous thromboembolism (VTE). Whether
RDW is a risk marker for thromboembolic events in AF patients is scarcely known. We
aimed to assess the association between RDWand the risk of AF, and AF-related VTE and
ischemic stroke, in a population-based cohort.
Methods We measured RDW in 26,111 participants from the Tromsø Study (1994–-
1995), and registered incident AF cases through December 31, 2013. Among
participants with AF, first-ever VTEs and ischemic strokes were registered from the
date of AF diagnosis through the end of follow-up. We calculated hazard ratios (HRs)
with 95% confidence intervals (CIs) for AF by quartiles of RDW. Furthermore, we
calculated cause-specific HRs for VTE and ischemic stroke by tertiles of RDW for
participants with AF.
Results There were 2,081 incident AF cases during a median of 18.8 years of follow-
up. Subjects with RDW in the highest quartile (RDW 13.3%) had 30% higher risk of AF
than those in the lowest quartile (RDW  12.3%). Among those with AF, subjects with
RDW in the upper tertile had a doubled risk of ischemic stroke (HR 2.07, 95% CI
1.20–3.57). In contrast, RDW was not associated with incident VTE in subjects with AF.
Conclusion RDW was significantly associated with incident AF in a general popula-
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Atrial fibrillation (AF) is the most prevalent arrhythmia of
clinical importance, and contributes extensively to morbidity
and mortality in the population.1–3 Ischemic stroke is gener-
ally considered the most detrimental complication of AF,4 but
recent studies have also established AF as a risk factor for
venous thromboembolism (VTE).5,6
Red cell distribution width (RDW) is an inexpensive and
easily available measure of variation in erythrocyte size.
Traditionally, RDW has been used in the differentiation of
anemias, but RDW has recently also emerged as a risk marker
for cardiovascular morbidity andmortality,7–9 includingmyo-
cardial infarction (MI),9 heart failure,10 ischemic stroke,11,12
and VTE.13,14A few studies have also implicated RDWas a risk
marker for AF.15–18 In a case–control study including 117
patients with AF and 60 controls, RDW was found to be
associated with AF in multivariable logistic regression analy-
sis,16 and in another case–control study by Liu et al, RDWwas
significantly higher in the AF group than in controls (12.7% vs.
12.4%; p< 0.05).17 A recent meta-analysis examining the
impact of hematological parameters on AF occurrence found
higherRDWinparticipantswithnew-onset AF comparedwith
those with sinus rhythm.19 Furthermore, RDW was signifi-
cantly increased in patients with AF recurrence.19
To what extent RDW is associated with thromboembolic
outcomes inpatientswithAFhas not beenextensively studied.
A dose–response relationship between increasing RDW and
riskof stroke inAF patientswas found in a large registry-based
study,20 while small case–control studies have reported
diverging results.21,22 Interestingly, increasing CHA2DS2-
VASC score, an established prediction score for thromboem-
bolism in AF patients,23,24waspositively correlatedwith RDW
levels in subjects with AF in several studies.17,20,25 Whether
RDW contributes to the excess VTE risk in patients with AF is
not known.
In the present study, we aimed to assess (1) the association
between RDWand incident AF in a general population cohort,
and (2) whether RDWwas associatedwith incident thrombo-
embolism (VTE and ischemic stroke) in subjects with AF.
Methods
Study Population
Participants were recruited from the fourth survey of the
Tromsø Study, an ongoing, prospective health study of the
inhabitants of Tromsø, Norway. The fourth survey was per-
formed in 1994 to 1995, and all inhabitants in the Tromsø
municipality aged  25 years were invited to participate. In
total, 27,158 persons aged 25 to 97 years attended the study,
comprising 77% of the eligible population. We excluded those
who withdrew their consent to medical research after the
Tromsø Study inclusion date (n¼ 166), participants not offi-
cially registered as residents of Tromsø (n¼ 22), participants
with AF prior to the inclusion date (n¼ 234), and personswith
missing RDW measurements (n¼ 625). A total of 26,111
participants were included in the study and followed from
the date of enrolment to December 31, 2013. Incident cases of
AF during follow-up were registered. In secondary analyses,
personswithVTE (n¼ 82)or ischemic stroke (n¼ 200)prior to
AF diagnosis were excluded, and VTE and ischemic stroke
events were recorded in all persons with a first lifetime
diagnosis of AF (n¼ 1,812) from the day of AF diagnosis until
the end of follow-up. All participants provided informed,
written consent, and the Regional Committee for Medical
and Health Research Ethics approved the study.
Baseline Measurements
Nonfasting blood samples, self-administered questionnaires,
and a physical examination were used to obtain baseline
information on all study participants. For the blood cell
parameters measurements, including RDW, 5mL of blood
was drawn from an antecubital vein into a vacutainer contain-
ing EDTA as an anticoagulant, and analyzedwithin 12 hours in
an automated blood cell counter (Coulter Counter, Coulter
Electronics, Luton, United Kingdom). RDW was calculated by
dividing the standard deviation of mean corpuscular volume
(MCV) by each person’s MCV value and multiplying by 100 to
convert to a percentage.26 The analytic coefficient of variation
of theRDWmeasurementswas less than 3%. All blood samples
were taken at the inclusion date (in 1994/1995). Serum total
cholesterol was measured as previously described.27 Blood
pressure measurements were performed using an automatic
device (Dinamap Vital Signs Monitor, 1846; Critikon Inc.,
Tampa, Florida, United States). After 2minutes seated rest,
three recordingswere takenontheupper right armat intervals
of1minute, and themeanof thelast twovalueswasused in the
analyses. Participants with systolic blood pressure  140mm
Hg, diastolic blood pressure  90mm Hg, or currently using
antihypertensive drugs were classified as having hyperten-
sion.Height andweightweremeasuredwith theparticipant in
light clothing and no shoes. Body mass index (BMI) was
calculated as weight in kilograms divided by the height in
meters squared (kg/m2). Self-administered questionnaires
were used to obtain information on diabetes mellitus and
current smoking status. Information on priorMIwas obtained
from the cardiovascular outcome registry of the Tromsø Study.
Ascertainment of Atrial Fibrillation
Incident AF was identified by searching the discharge diag-
nosis registry at the University Hospital of North Norway, the
sole provider of hospital care for the entire Tromsø munici-
pality, and the Norwegian Cause of Death Registry provided
by the Norwegian Institute of Public Health. The Tromsø
Study participants’ unique identification numbers were
linked to these diagnostic registries using the International
Classification of Diseases, Ninth Revision (ICD-9) codes 427.0
to 427.99 and Tenth Revision (ICD-10) codes I47 and I48. For
subjects with a diagnosis of cardiovascular or cerebrovascu-
lar disease, but without a registered arrhythmia diagnosis,
paper versions of hospital records (used until 2001) were
manually searched for anymention of AF, and the term “atrial
fibrillation” was used for text searches in the electronic
records. Trained personnel reviewed each potential AF case’s
medical record. All definite AF diagnoses required electro-
cardiogram documentation, and were adjudicated by an
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independent endpoint committee. When possible, the AF
events were further classified into paroxysmal and persis-
tent versus permanent forms. Participants who had parox-
ysmal AF initially, but who eventually developed a
permanent form, were classified as having permanent AF.
Persons with transient AF occurring only in relation to
cardiac surgery or an acute MI, and subjects who only had
AF in the terminal phase (the last week) of life were not
classified as having AF.28
Ascertainment of Venous Thromboembolism
We identified all incident VTE events by searching the
hospital discharge diagnosis registry, the autopsy registry,
and the radiology procedure registry at the University
Hospital of North Norway as previously described in
detail.29 Trained personnel reviewed the medical records
of each potential VTE event for case validation. A VTE
episode was recorded as a validated outcome only when
clinical VTE symptoms were present and combined with
confirmatory tests (compression ultrasonography, venogra-
phy, spiral computed tomography, perfusion–ventilation
scan, pulmonary angiography, or autopsy), resulting in a
VTE diagnosis that required treatment. For the VTE events
retrieved from autopsy records, a validated event was
recorded when the death certificate designated VTE as
the cause of death or a significant condition contributing
to death. The VTE event was further classified as unpro-
voked (no provoking factors) or provoked ( one provoking
factor[s]) based on the presence of provoking factors at the
time of diagnosis. Immobilization (bed rest  3 days,
wheelchair, long haul travel  4 hours within 14 days prior
to the event), major surgery, trauma, or an acute medical
condition (acute MI, ischemic stroke, or major infectious
disease) within 8 weeks prior to the event, active cancer, or
other potential provoking factors described by a physician
in the medical record (e.g., intravascular catheter) were
regarded as provoking factors.
Ascertainment of Ischemic Stroke
Information on incident ischemic stroke was obtained by
linkage to the diagnosis registries at the University Hospital
of North Norwayand the Norwegian Cause of Death Registry,
using an expansive search for the ICD-8 and -9 codes
430–438, and ICD-10 codes I60–I69 (cerebrovascular dis-
eases). Systematic text searches in the medical records for
patients with ICD-8 and -9 diagnosis codes 410–414 and
798–799, and ICD-10 codes I20–I25 and R96, R98, and R99
were additionally performed to ensure case completeness.
The WHO definition was used to define ischemic stroke:
Rapidly developing clinical signs of focal or global distur-
bance of cerebral function, with symptoms lasting 24 hours
or longer or leading to death, with no apparent cause other
than vascular origin.30 Furthermore, imaging tests (comput-
ed tomography or magnetic resonance imaging) or an autop-
sy were required to exclude intracerebral or subarachnoid
hemorrhage. An independent endpoint committee followed
a detailed protocol according to established diagnostic crite-
ria for case validation.
Statistical Analyses
We performed statistical analyses using STATA, version 15
(Stata Corporation, College Station, Texas, United States). For
analysis of the association between RDW and AF, crude inci-
dence rates (IRs) with 95% confidence intervals (CIs) were
calculated as the total number of events divided by total
person-time at risk, and expressed as events per 1,000 per-
son-years. Cox proportional hazards regression models were
used to estimate hazard ratios (HRs) with 95% CI for AF by
increasing levels of RDW. To assess for nonlinearity or a
potential threshold effect, participants were categorized into
quartiles based on the distribution of baseline RDW, and the
lowest quartile was used as reference. Additionally, a cutoff
wasfixedat the95thpercentile.Model 1 includedage, sex, and
BMI, model 2 included the variables of model 1, as well as
hemoglobin,whiteblood cells, and platelet count, andmodel 3
included the variables of model 2, as well as smoking, hyper-
tension, diabetes, previous MI, and total cholesterol. We used
chronological age as the time scale in the regression models,
defining the participants’ age at study enrollment as entry
time, and the age at the timeofAFdiagnosis or censoring event
(i.e., migration, death, or study end) as exit time.
In analyses regarding the riskof VTE and ischemic strokeby
RDW levels in the AF population, tertiles based on thebaseline
RDWdistributionwere chosen for the categorical analyses due
to thesmaller populationsize.Cause-specificCoxproportional
hazards models were used to estimate HRs with 95% CIs for
VTE and ischemic stroke. In the cause-specific models, the AF
patients were followed to the first occurrence of VTE or stroke
(e.g., in theanalysesof stroke risk, a participantwhodeveloped
VTEbefore a strokewould be censored at the date of VTE). Age
at AF diagnosiswas used as entry time, and the age at the time
of a censoring event (i.e., VTE, ischemic stroke, migration,
death, or study end) as exit time. The number of participants
included in the adjusted regressionmodels varied slightly due
to missing data for some covariates (in total 1.5%missing). We
tested the assumption of proportional hazards assumption
using Schoenfeld residuals and found no violation. Statistical
interactions between RDW and sex were tested by including
cross-product terms of sex and RDW into the models, and no
interactions were found.
Results
A total of 2,082 participants (8.0%) experienced incident AF
during amedian follow-up time of 18.8 years, yielding a crude
IR of 4.7 per 1,000 person-years. Themean age at AF diagnosis
was 75.0 years (range 34.3–103.1 years). ThemeanRDWof the
study populationwas 12.9%with a standard deviation of 0.93.
Baseline characteristics of study participants across quartiles
of RDW are shown in ►Table 1. The mean age at study
inclusionwas 12.5 years higher for participants in the highest
versus the lowestquartileofRDW.Whitebloodcell count, BMI,
total cholesterol, and the prevalence of daily smoking, diabe-
tes, prior MI, and hypertension increased across quartiles of
RDW (►Table 1). Participants who developed AF during
follow-up were older, had higher BMI, and total cholesterol
levels, and a higher prevalence of diabetes and prior MI
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comparedwith participantswithout AF (►Table 2). Hemoglo-
bin levels andwhitebloodcell countswerehigher in thosewith
AF, while there were more daily smokers among participants
without than with AF (►Table 2).
Crude IRs and HRs for AF across quartiles of RDW are
shown in ►Table 3. Participants with RDW in the highest
quartile had 32% increased risk of incident AF comparedwith
those in the lowest quartile in analyses adjusted for age, sex,
and BMI (HR 1.32, 95% CI 1.14–1.52). The relative risk
estimates remained unchanged after further adjustment
for hematological parameters (model 2), and barely altered
after addition of cardiovascular risk factors to the regression
model (model 3) (►Table 3). Given the wide range of RDW in
the highest quartile (13.3–30.5), we performed sensitivity
analyses excluding participants with RDW measurements
above the 95th percentile ( 14.4%), and found similar risk
estimates as for the full cohort (data not shown). Participants
with RDW measurements above the 95th percentile (
14.4%) had a similar 1.3-fold increased VTE risk when
compared with participants in the lowest quartile (multivar-
iable HR 1.30, 95% CI 1.04–1.63) (►Table 3). When modeling
RDW as a continuous variable, a 1% increment in RDW was
associated with a 7% increased risk of AF (HR 1.07, 95% CI
1.02–1.12) after multivariable adjustment (►Table 3). We
also performed age-stratified analyses inwhich the risk of AF
was assessed in participants younger than and older than
60 years of age at inclusion. When comparing those in the
highest versus the lowest quartile of RDW, the positive
association was slightly more pronounced in the youngest
age group, but the CIs overlapped (multivariable HR 1.38
[95% CI 1.11–1.74] and 1.27 [95% CI 1.09–1.49] for those 
60 years and those< 60 years, respectively) (data not
shown). To investigate whether the association between
RDW and AF was modified by anemia, we performed analy-
ses in which women with hemoglobin levels< 12 g/L
(n¼ 976) and men with hemoglobin levels< 13 g/L
(n¼ 338) were excluded. In analyses adjusted for BMI and
sex, the risk estimates for nonanemic participants in the
highest RDW quartile did not differ from that observed for
the total population (HR 1.33, 95% CI 1.15–1.54) (data not
shown).
Among the 2,082 participants who developed AF during
follow-up, 270 persons had an ischemic stroke (n¼ 190) or
VTE (n¼ 80) before theAF diagnosis, andwere excluded from
the cause-specific analyses of RDW as a risk marker for AF-
Table 2 Baseline characteristics by development of atrial





RDW (%) 12.9 0.9 13.1 0.9
Age (y) 45.3 14.4 62.7 11.8
Sex (male, %) 46.6 (11,205) 54.4 (1,133)
Body mass index (kg/m2) 25.0 3.8 26.9 4.3
Total cholesterol (mmol/L) 6.0 1.3 6.7 1.2
Hypertensiona (%) 32.5 (7,804) 69.6 (1,449)
Self-reported diabetes (%) 1.4 (344) 4.7 (98)
Daily smoking (%) 37.8 (9,070) 27.9 (579)
History of myocardial
infarction (%)
7.7 (1,861) 31.3 (651)
Hemoglobin (total) (g/dL) 14.0 1.2 14.3 1.1
White blood cells ( 109/L) 7.1 2.0 7.0 2.0
Platelets, 109/L 254 56 242 56
Abbreviations: AF, atrial fibrillation; RDW, red cell distribution width.
Note: Values are given as percentages with numbers in brackets or as
means with standard deviations.
aDefined as systolic blood pressure  140mm Hg or diastolic blood
pressure  90mm Hg or self-reported use of antihypertensive
medication.









RDW range (%) 10.7–12.3 12.4–12.7 12.8–13.2 13.3–30.5
Age (y) 40.7 12.3 44.6 13.8 48.6 14.7 53.2 15.9
Sex (male, %) 46.1 (3,022) 49.0 (3,271) 49.5 (3,274) 44.2 (2,771)
Hemoglobin (g/dL) 14.1 1.1 14.2 1.1 14.1 1.1 13.7 1.4
White blood cells ( 109/L) 6.9 1.8 7.0 2.1 7.1 2.0 7.3 2.2
Platelets ( 109/L) 251 51 249 52 251 55 260 66
Body mass index (kg/m2) 24.7 3.5 25.1 3.7 25.3 3.9 25.5 4.2
Total cholesterol (mmol/L) 5.7 1.2 6.0 1.3 6.2 1.3 6.3 1.4
Diabetes (%) 1.4 (88) 1.6 (105) 1.6 (128) 1.9 (121)
History of myocardial infarction (%) 4.4 (290) 7.3 (489) 11.2 (739) 15.9 (994)
Hypertensiona (%) 26.7 (1,745) 32.6 (2,179) 37.3 (2,469) 45.6 (2,860)
Abbreviation: RDW, red cell distribution width.
Note: Values are given as percentages with numbers in brackets or as means with standard deviations.
aDefined as systolic blood pressure  140mm Hg or diastolic blood pressure  90mm Hg or self-reported use of antihypertensive medication.
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related thromboembolism. The remaining 1,812 participants
with AF were followed for a median of 3.7 years, and there
were 264 incident ischemic strokes and 87 VTEs during
follow-up. Among the VTE events, 53 (61%) were pulmonary
embolisms (PEs) and 34 (39%) were deep vein thromboses
(DVTs). Fifty-eight (66.7%) of the VTE events had one ormore
provoking factor present at the time of diagnosis, and among
the provoked events, 50%were attributed to an acutemedical
condition within 8 weeks prior to the VTE. Seventeen par-
ticipants experienced both ischemic stroke and VTE during
follow-up, and for these participants, follow-up ended when
their first thromboembolic event occurred (VTE first¼ 5,
stroke first¼ 12). The calculated crude IRs and HRs for VTE
and ischemic stroke across tertiles of RDW are shown
in ►Table 4. Crude IRs for ischemic stroke were significantly
higher in the highest tertile (IR 4.00 per 100 person-years,
95% CI 3.26–4.90) versus the lowest tertile (IR 2.30 per 100
person-years, 95% CI 1.84–2.89) of RDW. Furthermore, par-
ticipants with RDWmeasurements in the highest tertile had
a 51% increased risk of ischemic stroke compared with those
in the lowest tertile after multivariable adjustment (HR 1.51,
95% CI 1.09–2.10) (►Table 4). On the other hand, there was
no apparent increased risk of VTE by increasing RDW tertiles
in any of the regression models (►Table 4). In subgroup
analyses, RDW was not associated with either PE or DVT
(data not shown).
Discussion
In this population-based cohort study, we confirmed an
association between RDW and incident AF and expanded
the current knowledge on the impact of RDW on the risk of
thromboembolic events in AF patients. The risk of ischemic
stroke, but not VTE, was higher with increasing RDW in AF
patients.
Our finding of RDW as a risk marker for incident AF is in
concurrence with previous reports. In a comparable cohort
from the Malmö Diet and Cancer Study,15 similar HRs for AF
by RDW as those obtained in our study were reported. In
their study, the highest quartile of RDWwas associated with
a 1.3-fold increased risk of AF after multivariable analyses,
and a 1% increment in RDW was associated with an 8%
increase in AF risk.15 Similarly, Li et al found elevated RDW
to be significantly associated with prevalent AF in a recently
published Chinese cross-sectional study.18 In a meta-analy-
sis comprising 2,721 participants with AF, higher baseline
RDW was associated with incident AF, but there was signifi-
cant heterogeneity across the studies.31
The biological mechanisms linking increasing RDW to AF
areunclear.High levelsofRDWmayreflectoxidativestressand
inflammation, as these factors shorten the life span of red
blood cells and hamper bone marrow function, leading to a
more heterogeneous erythrocyte population.32,33 As AF is
associated with both systemic inflammation and oxidative
stress,34,35 the association with RDW may partially be medi-
ated through these factors. In the present study, we found that
the association between RDWandAFwas virtually unchanged
after adjustment for white blood cell count, suggesting that
other mechanisms than inflammation may be involved in the
interplay between RDW and AF. This is in concurrence with a
previous report from the Tromsø Study, in which the associa-
tion between RDW and MI and ischemic stroke was only
slightly attenuated after adjustments for C-reactive protein.36
Adirecteffectoferythrocytedysfunctiononthemyocardium
may contribute to the development of AF. A heterogeneous
erythrocyte population may have lower deformability and
decreased oxygen-carrier capacity,37 contributing to reduced
myocardial oxygenation and cardiac dysfunction,38 in turn
triggering AF. An association between reduced erythrocyte
deformability and cardiac arrhythmias has been demonstrated
Table 3 Crude incidence rates per 1,000 person‐years and adjusted hazard ratios with 95% confidence intervals for atrial fibrillation
by quartiles of red cell distribution width (the Tromsø Study 1994–2013)
RDW Persons Median RDW,
% (range)
Person-years Events IR HR, model 1a HR, model 2b HR, model 3c





















































Abbreviations: IR, incidence rate; HR, hazard ratio; RDW, red cell distribution width.
aAge as time scale, adjusted for sex and body mass index.
bAge as time scale, adjusted for sex, body mass index, hemoglobin, white blood cells, and platelets.
cAge as time scale, adjusted for sex, body mass index, hemoglobin, white blood cells, platelets, smoking, hypertension, self-reported diabetes,
previous myocardial infarction, and total cholesterol.
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previously.39 As addressed by a recent review,40 anemia is
associated with both AF development and increased RDW.40
In the present study, risk estimates for AFwere not significantly
modified by adjusting for hemoglobin levels in the regression
models, nor by excluding anemic participants from the multi-
variable analyses.
Previous observational studies, including reports from the
TromsøStudy, have reported an increased riskof bothVTE13,14
and ischemic stroke11,12 by RDW in the general population.
Several mechanisms underlying these associations have been
postulated, including inflammatory conditions, renal dysfunc-
tion, malnutrition, and oxidative damage.41 Increased RDW
has also beenassociatedwithdecreased redblood cell deform-
ability,37which increases erythrocyte aggregation,42 and thus
may trigger thrombosis.43 A few studies have previously
exploredwhether increasing RDW is associatedwith an excess
risk of thromboembolism in AF patients.20,44–46 In accordance
with our results, Saliba et al found RDW to be associated with
both absolute and relative risks of stroke in subjectswith AF.20
In their population-based registry study, the stroke risk was
33% higher among AF patients in thehighest versus the lowest
quartile of RDW.20 Similarly, in a retrospective study of 5,082
patients with AF, RDW values  13.9% conferred a 1.7-fold
increased risk of thromboembolic events (ischemic stroke and
peripheral embolism) compared with RDW< 13.9%.45 Al-
though AF is a risk factor for incident VTE,6,47,48 RDW meas-
ures did not affect VTE risk in the present AF cohort.
The mechanisms behind the differential impact of RDW
measures on the two thromboembolic outcomes are not
known. RDW measures correlate with the CHA2DS2-VASC
score,17,25,46 whose components (Congestive heart failure,
Hypertension, Age> 75, Diabetes mellitus, Stroke/TIA/throm-
boembolism, Vascular disease, Age 65–74, Sex [female]), are
associated with stroke risk in AF patients. In contrast, neither
hypertension, diabetes mellitus, nor female gender have been
associated with VTE risk in prospective studies.27,49 Thus, it is
possible that the excess risk of stroke by RDW in AF patients to
some extent reflects a burden of cardiovascular risk factors
that have little impact on VTE risk.50
The thrombosis potential model proposed by Rosendaal
two decades ago emphasizes the multicausal nature of VTE.51
The model illustrates how a VTE develops once sufficient risk
factors have accumulated in a patient, and that VTE risk factors
have synergistic effects.51 We have previously demonstrated
that the riskofPE in thefirst 6months followingAFdiagnosis is
11-fold higher when compared with subjects without AF,
largely exceeding the comparable risk estimates for ischemic
stroke.48 In the present study, we observed a majority of
Table 4 Crude incidence rates per 100 person-years and hazard ratios for incident venous thromboembolism and ischemic stroke
by red cell distribution width in subjects with atrial fibrillation (the Tromsø Study 1994–2013)
Persons Median RDW,
% (range)






























































































Abbreviations: IR, incidence rate; HR, hazard ratio; RDW, red cell distribution width.
aAge as time scale, adjusted for sex and body mass index.
bAge as time scale, adjusted for sex, body mass index, hemoglobin, white blood cells, and platelets.
cAge as time scale, adjusted for sex, body mass index, hemoglobin, white blood cells, platelets, smoking, hypertension, self-reported diabetes,
previous myocardial infarction, and total cholesterol.
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provokedVTEs among theAFpatients, andone-third of all VTE
had suffered an acute medical condition within 8 weeks prior
toVTEdiagnosis. In concurrencewith thethrombosispotential
model, it is plausible that the accumulated risk factors in the
present population (high age, AF, hospitalizations, and comor-
bidities) dilute the additional impact of RDW on VTE risk.
Our study has several strengths, including the large
number of participants recruited from a general population,
and the prospective design with a mean follow-up of almost
19 years. The high attendance rate reduces the risk of
selection bias, and the detailed validation of exposures and
outcome ensures a clear temporality of events. Several
limitations also merit attention. RDW was only measured
at inclusion, and may have fluctuated over time. Unfortu-
nately, repeated measurements of RDW are not available for
the Tromsø Study population. Nevertheless, nondifferential
misclassification of this kind generally leads to an underes-
timation of true associations. In an earlier report from the
Tromsø Study, we found that risk estimates for VTE based on
baseline measurements of cardiovascular risk factors
(time-fixed analyses) in general corresponded well with
risk estimated based on repeatedmeasurements (time-vary-
ing analyses).52 The true incidence of AF in our study may be
underestimated, as many episodes of AF are asymptomatic.
Furthermore, patients with AF exclusively treated in general
practice are not included. We lacked information on heart
failure and the use of antithrombotic medication. As the
latter effectively reduces thrombosis risk in AF patients, it is
possible that we underestimate the true risk of VTE and
ischemic stroke by RDW in our AF population. Furthermore,
not having information on heart failure makes it difficult to
assess the implementation of RDW to existing prediction
scores in AF. Among the AF patients, the number of VTE
events was small, and our study may be underpowered to
detect weak associations.
In conclusion, RDW showed an association with incident
AF. In patients with AF, RDW further aggravated the risk of
ischemic stroke, but not the risk of VTE.
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